‌

Register

Login

Vet Times logo
+
  • View all news
  • Vets news
  • Vet Nursing news
  • Business news
  • + More
    • Videos
    • Podcasts
  • View all clinical
  • Small animal
  • Livestock
  • Equine
  • Exotics
  • Vet Times jobs home
  • All Jobs
  • Your ideal job
  • Post a job
  • Career Advice
  • Students
About
Contact Us
For Advertisers
NewsClinicalJobs
Vet Times logo

Vets

All Vets newsSmall animalLivestockEquineExoticWork and well-beingOpinion

Vet Nursing

All Vet Nursing newsSmall animalLivestockEquineExoticWork and well-beingOpinion

Business

All Business newsHuman resourcesBig 6SustainabilityFinanceDigitalPractice profilesPractice developments

+ More

VideosPodcastsDigital Edition

The latest veterinary news, delivered straight to your inbox.

Choose which topics you want to hear about and how often.

Vet Times logo 2

About

The team

Advertise with us

Recruitment

Contact us

Vet Times logo 2

Vets

All Vets news

Small animal

Livestock

Equine

Exotic

Work and well-being

Opinion

Vet Nursing

All Vet Nursing news

Small animal

Livestock

Equine

Exotic

Work and well-being

Opinion

Business

All Business news

Human resources

Big 6

Sustainability

Finance

Digital

Practice profiles

Practice developments

Clinical

All Clinical content

Small animal

Livestock

Equine

Exotics

Jobs

All Jobs content

All Jobs

Your ideal job

Post a job

Career Advice

Students

More

All More content

Videos

Podcasts

Digital Edition


Terms and conditions

Complaints policy

Cookie policy

Privacy policy

fb-iconinsta-iconlinkedin-icontwitter-iconyoutube-icon

© Veterinary Business Development Ltd 2025

IPSO_regulated

7 May 2025

Trust warning as petition demands Librela axe

Makers of the canine osteoarthritis treatment have defended its safety record, insisting all of the issues observed were either rare or very rare.

author_img

Allister Webb

Job Title



Trust warning as petition demands Librela axe

Image: Alernon77 / Adobe Stock

Trust in the veterinary sector is being undermined by the scale of adverse reactions linked to a prominent treatment for canine osteoarthritis, an online petition has claimed.

Campaigners have demanded a halt to sales of Librela in the UK and an inquiry into both its effects and how it was approved for use.

A newly published paper has also revealed thousands of adverse event cases have been linked to the product, although its maker Zoetis insisted it “[remains] confident” of its safety and effectiveness.

‘Careless use’

More than 1,560 people have so far signed the petition, launched via the change.org website, which seeks to stop what it calls “the careless use and sale of Librela in the UK”.

It further demanded an inquiry into the product’s effects and the approval process for its use in the UK, plus clearer communication about its potential risks.

The campaign was launched by a pet owner who said her dog became ill after being treated with Librela, despite claimed assurances that it would not have side effects.

The petition continued: “The volume of these adverse reactions undermines the trust placed in our veterinary professionals and raises questions about their motivations in promoting such a hazardous drug.

“Recognising that our pets are not just animals but cherished members of our families, it is essential that their health and well-being are protected by those in a position to stop the sale and use of Librela in the UK.”

New paper

The petition’s launch preceded the release of a new paper, co-authored by two senior Zoetis officials, which revealed that more than 17,000 adverse event cases linked to Librela were reported globally between February 2021 and June of last year.

But the study, published in Frontiers of Veterinary Science, also reported that more than 18 million doses of the drug were sold over the same period.

In response to the petition, a Zoetis spokesperson said: “Since launching four years ago, Librela has been used effectively with millions of dogs around the world, helping dogs suffering from osteoarthritis pain live with less pain and greater mobility.”

The spokesperson continued: “We remain confident in the safety and effectiveness of Librela for controlling osteoarthritis pain in dogs, when used according to the label, and in the science, safety and regulatory rigour behind this product.”

The paper also argued that no “causal relationship” had been established between the drug and deaths that occurred after it was used.

Rare

Meanwhile, each of the most common types of adverse events linked to it were classed as rare, meaning between 1 and 10 events per 10,000 treated animals, or very rare, meaning fewer than one in 10,000 animals were affected. But the UK was found to have a significantly higher proportion of adverse events, 14.61 per 10,000 doses, than the overall global frequency, though the paper said it was “difficult to speculate” on the reasons for fluctuation between individual jurisdictions.

The VMD said it had “continuously monitored” Librela since it was first authorised and would take action where it was felt to be appropriate.

A spokesperson added: “We would always advise the public to seek advice from their veterinary professional before providing medicine to their animals.”

‌
‌
‌